BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
11/27/2025 7:54:00 AM | Browse: 40 | Download: 119
 |
Received |
|
2025-07-31 02:20 |
|
Peer-Review Started |
|
2025-07-31 02:20 |
|
First Decision by Editorial Office Director |
|
2025-08-19 09:15 |
|
Return for Revision |
|
2025-08-19 09:15 |
|
Revised |
|
2025-08-26 01:33 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2025-11-06 02:43 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2025-11-06 08:14 |
|
Articles in Press |
|
2025-11-06 08:14 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2025-11-17 01:04 |
|
Publish the Manuscript Online |
|
2025-11-27 07:54 |
| ISSN |
1948-5182 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Minireviews |
| Article Title |
Redefining fatty liver as metabolic dysfunction-associated steatotic liver disease: Implications of nomenclature changes for patients with diabetes
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Tulio L Correa and Nikki Duong |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Tulio L Correa, MD, Post Doctoral Researcher, Division of General Internal Medicine, University of Pittsburgh Medical Center, No. 200 Lothrop Street, Pittsburgh, PA 15222, United States. correatl@upmc.edu |
| Key Words |
Non-alcoholic fatty liver disease; Fatty liver; Diabetes mellitus; Metabolic dysfunction-associated steatotic liver disease; Type 2 diabetes mellitus |
| Core Tip |
The transition from non-alcoholic fatty liver disease to metabolic dysfunction-associated steatotic liver disease refocuses diagnosis on metabolic dysfunction, capturing a broader spectrum of patients with type 2 diabetes mellitus and hepatic steatosis. Metabolic dysfunction-associated steatotic liver disease and its related category, metabolic and alcohol-associated liver disease, improve disease recognition, prevalence estimation, and management strategies compared to non-alcoholic fatty liver disease. This minireview highlights the clinical implications of these changes, including the need for reclassification in trials, metabolic-targeted treatments, and multidisciplinary approaches to enhance screening and outcomes in type 2 diabetes mellitus populations. |
| Publish Date |
2025-11-27 07:54 |
| Citation |
Correa TL, Duong N. Redefining fatty liver as metabolic dysfunction-associated steatotic liver disease: Implications of nomenclature changes for patients with diabetes. World J Hepatol 2025; 17(11): 112573 |
| URL |
https://www.wjgnet.com/1948-5182/full/v17/i11/112573.htm |
| DOI |
https://dx.doi.org/10.4254/wjh.v17.i11.112573 |
© 1993-2026 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
